 SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, March 02, 2021 GLOBE NEWSWIRE -- TLC Nasdaq: TLC, TWO: 4152, a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced that the Companys management team will be presenting at the following virtual investor conferences: 